KRT18 and metabolic dysfunction-associated steatohepatitis: In addition, our dose–response results were consistent with the findings of a phase 2 trial of semaglutide among patients with NASH [40], showing dose-dependent reductions in liver-related biomarkers (i.e., ALT, AST, and cytokeratin-18 fragments).